{
  "name" : "twin.sci-hub.se_6198_8c351a0ebfafe680d7a6d253948a34e2_kamran2016.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment",
    "authors" : [ "Mohd. Kamran", "Abdul Ahad", "Mohd. Aqil", "Syed Sarim Imam", "Yasmin Sultana", "Asgar Ali" ],
    "emails" : [ "aqilmalik@yahoo.com", "abdulahad20@yahoo.com,", "aahad@ksu.edu.sa" ],
    "sections" : [ {
      "heading" : null,
      "text" : "Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment\nMohd. Kamrana, Abdul Ahadb, Mohd. Aqila,*, Syed Sarim Imamc, Yasmin Sultanaa, Asgar Alia\na Faculty of Pharmacy, Jamia Hamdard (Hamdard University), M.B. Road, New Delhi 110062, India bDepartment of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia cGlocal School of Pharmacy, Glocal University, Saharanpur, Uttar Pradesh 247121, India\nA R T I C L E I N F O\nArticle history: Received 4 January 2016 Received in revised form 16 March 2016 Accepted 18 March 2016 Available online 19 March 2016\nChemical compounds studied in this article: Acetonitrile (PubChem CID: 6342) Carbopol 934 (PubChem CID: 6581) Chloroform (PubChem CID: 6212) Ethanol (PubChem CID: 702) Ethylenediaminetetraacetic acid (PubChem CID: 6049) Isopropyl alcohol (PubChem CID: 3776) Methanol (PubChem CID: 887) Olmesartan medoxomil (PubChem CID: 130881) Phosphotungstic acid (PubChem CID: 16212977) Polyethylene glycol-400 (PubChem CID: 174) Potassium dihydrogen phosphate (PubChem CID: 516951) Rhodamine B (PubChem CID: 6694) Sodium hydroxide (PubChem CID: 14798) Triethanolamine (PubChem CID: 7618) b-citronellene (PubChem CID: 10887985)\nKeywords: Nano-invasomes Transdermal Olmesartan Pharmacokinetics Box-Behnken design\nA B S T R A C T\nOlmesartan is a hydrophobic antihypertensive drug with a short biological half-life, and low bioavailability, presents a challenge with respect to its oral administration. The objective of the work was to formulate, optimize and evaluate the transdermal potential of novel vesicular nano-invasomes, containing above anti-hypertensive agent. To achieve the above purpose, soft carriers (viz. nanoinvasomes) of olmesartan with b-citronellene as potential permeation enhancer were developed and optimized using Box-Behnken design. The physicochemical characteristics e.g., vesicle size, shape, entrapment efficiency and skin permeability of the nano-invasomes formulations were evaluated. The optimized formulation was further evaluated for in vitro drug release, confocal microscopy and in vivo pharmacokinetic study. The optimum nano-invasomes formulation showed vesicles size of 83.35 3.25 nm, entrapment efficiency of 65.21 2.25% and transdermal flux of 32.78 0.703 (mg/ cm2/h) which were found in agreement with the predicted value generated by Box-Behnken design. Confocal laser microscopy of rat skin showed that optimized formulation was eventually distributed and permeated deep into the skin. The pharmacokinetic study presented that transdermal nano-invasomes formulation showed 1.15 times improvement in bioavailability of olmesartan with respect to the control formulation in Wistar rats. It was concluded that the response surfaces estimated by Design Expert1 illustrated obvious relationship between formulation factors and response variables and nano-invasomes were found to be a proficient carrier system for transdermal delivery of olmesartan.\nã 2016 Elsevier B.V. All rights reserved.\nContents lists available at ScienceDirect\nInternational Journal of Pharmaceutics\njournal homepage: www.elsev ier .com/locate / i jpharm\n* Corresponding author at: Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), M.B. Road, New Delhi 110062, India.\nE-mail addresses: aqilmalik@yahoo.com (M. Aqil), abdulahad20@yahoo.com, aahad@ksu.edu.sa (A. Ahad).\nhttp://dx.doi.org/10.1016/j.ijpharm.2016.03.030 0378-5173/ã 2016 Elsevier B.V. All rights reserved."
    }, {
      "heading" : "1. Introduction",
      "text" : "Hypertension is an important risk factor for cardiovascular disease and affects almost one-third of the U.S. adult population (Ong et al., 2008). Similar conditions have been observed in India; in an analysis data for the burden of hypertension, 20.6% of Indian\nmen and 20.9% of Indian women were suffering from hypertension in 2005 (Anchala et al., 2014; Kearney et al., 2005). The rates for hypertension in percentage are projected to go up to 22.9 and 23.6 for Indian men and women, respectively by 2025 (Kearney et al., 2005). Recent studies from India have shown that only about 25.6% of treated patients had their blood pressure under control, in a multicenter study from India on awareness, treatment, and adequacy of control of hypertension (Anchala et al., 2014).\nMost of the angiotensin II receptor blockers exhibit low oral bioavailability (losartan 30%, valsartan 10–35%, candesartan 15%, eprosartan 13%, telmisartan 42% and olmesartan 28.6%), they may be required to be taken more than once a day due to their short half-life (losartan 1.5–2 h, valsartan 7.5 h, candesartan 9 h, eprosartan 5–9, telmisartan 24 h, and olmesartan 10–15 h) that may results in patient non-compliance (Ahad et al., 2016). There is an ineluctable requirement for improved drug delivery devices for antihypertensive drugs considering the quantum of their utilization and short coming associated with their conventional dosage forms (Ahad et al., 2015a, 2013a, 2016). Many drugs have been introduced into the international market in the form of a transdermal therapeutic system (TTS); the number of such drugs is small considering the great promise of this system. Skin permeation has consistently been the main area of concern and a major deterrent in the marketing of such products (Ahad et al., 2015b). Currently, no angiotensin II receptor blocker which is an important antihypertensive class for the management of hypertension is commercially available as TTS by any pharmaceutical manufacturer.\nMany attempts have been made globally at the laboratory level to develop transdermal system of various antihypertensive drugs (Ahad et al., 2015a, 2013a, 2016; Gungor and Ozsoy, 2012; Selvam et al., 2010). Recently, Ahad et al. (2015a,b), reviewed and detailed the transdermal research specifically on angiotensin II receptor blockers for the management of hypertension (Ahad et al., 2016).\nOlmesartan medoxomil (Fig. 1) is an angiotensin II receptor blocker. Oral olmesartan 10–40 mg once daily is recommended for the treatment of adult patients with hypertension (Scott and McCormack, 2008). The oral bioavailability of olmesartan from olmesartan medoxomil tablets was 28.6% in humans (Brunner,\n2002; Laeis et al., 2001). It is a Biopharmaceutics classification system (BCS) class II drug having molecular weight of 446.50 Da with a log partition coefficient of 4.70, and half-life of 10–15 h. Above properties of olmesartan makes it a good candidate for the development of TTS (Ahad et al., 2016; Aqil et al., 2016; Hathout and Elshafeey, 2012).\nIn view of dearth of research literature on transdermal delivery of olmesartan, it seems that there is potential for investigating the olmesartan loaded invasomes system. The nano-invasomes were developed and optimized using Box-Behnken design and evaluated for vesicle size, shape, entrapment efficiency, in vitro skin permeation and in vivo pharmacokinetic study.\nInvasomes are flexible, neutrally charged, phospholipid based vesicular system containing a mixture of soy phosphatidylcholine, lyso phosphatidylcholine, terpenes, and ethanol. This system has shown to improve skin penetration of hydrophilic and lipophilic drugs (Dragicevic-Curic et al., 2008a,b, 2009a,b; Shah et al., 2015). Flexibility of the bilayer membrane is mainly due to the lyso phosphatidylcholine acting as an edge activator. Ethanol is a good penetration enhancer while terpenes have also shown potential to increase the penetration of many drugs by disrupting the tight lipid packing of the stratum corneum (Aqil et al., 2007). In present study, b-citronellene was used in the composition of the soft vesicular systems. b-citronellene has been previously identified as a promising permeation enhancer for transdermal delivery of hydrophilic and lipophilic drugs (Ahad et al., 2011a,b). b-citronellene has melting point (154–155 C) with a log partition coefficient (5.012) and it was found better permeation enhancer than other several investigated terpenes for transdermal delivery of valsartan (Ahad et al., 2011b). Very recently, invasomes prepared using b-citronellene were described as carriers for skin deposition of isradipine (Qadri et al., 2016)."
    }, {
      "heading" : "2. Materials and methods",
      "text" : ""
    }, {
      "heading" : "2.1. Materials",
      "text" : "Olmesartan medoxomil was received as a gift sample from Ranbaxy Research Laboratory (Haryana, India). The commercially available tablets formulation of olmesartan medoxomil (BENICAR1 20 mg) was purchased from Daiichi Sankyo, Inc., Parsippany, New Jersey. Phospholipon190 G was received as a gratis sample from Phospholipid GmbH Nattermannallee, Germany and ethanol was purchased from Changshu Yangquan Chemical, China. b-citronellene (Fig. 1) claimed with 98.5% purity was purchased from Sigma-Aldrich Chemicals Private Limited, New Delhi, India. Carbopol1 934, Polyethylene glycol-400, and triethanolamine were purchased from S.D. Fine Chemicals, India. Water for high performance liquid chromatography (HPLC) was prepared by a Milli-Q-purification system. All other chemicals used were of reagent grade. All materials were used as received."
    }, {
      "heading" : "2.2. Preparation of nano-invasomes",
      "text" : "10 ml of nano-invasomes were prepared by the method as reported elsewhere (Shah et al., 2015). In brief, Phospholipon1 90 G and olmesartan (10 mg) were dissolved in 10 ml of methanol: chloroform mixture (1:2, v/v) in a round bottom flask. Thin lipid films were obtained by removing the organic solvents under vacuum condition (500 mbar 10 min, 200 mbar 10 min, 100 mbar 10 min, 35 mbar 1 h) at a temperature more than transition temperature of lipid with a rotary evaporator (Model HS 2005V-N, Hahnshin Scientific Co., Korea). The traces of solvent were removed from the deposited lipid film under vacuum overnight. To the lipid film, terpene was added followed by addition of filtered phosphate buffered saline pH 7.4 (PBS) and ethanol in different levels\n(Table 1). The lipid film was hydrated to form a suspension with 9% total lipid (by weight) which presented multilamellar vesicles. The obtained multilamellar vesicles were sonicated for 15 min in 3 cycles (5 min for each cycle with 5 min pause among these cycles) with a Titanium probe ultrasonicator (Ultrasonicator, ModelUP100H, Hielscher Ultrasonics GmbH, Berlin) to produce nanoinvasomes."
    }, {
      "heading" : "2.3. Box-Behnken design for optimization of nano-invasomes",
      "text" : "Statistical Box-Behnken design was used for the optimization procedure of nano-invasomes formulation. The applied design showed 15 experimental runs (Table 2), for which quadratic model is termed as: Y = b0 + b1X1 + b2X2 + b3X3 + b12X1X2 + b13X1X3 + b23X2X3 + b11X12 + b22X22 + b33X32. Where Y is the measured response associated with each factor level combination; b0 is constant; b1, b2, b3 are linear coefficients, b12, b13, b23 are interaction coefficients among three factors, b11, b22, b33 are quadratic coefficients of observed experimental values; and X1, X2 and X3 are mentioned levels of independent variables. The design employed three-factor, three- level Box-Behnken design using Design-Expert 9.0.3.1 software (Stat-Ease Inc., Mineapolis, USA). The chosen independent variables were phospholipid (X1), ethanol (X2), and b-citronellene (X3), while vesicles size (Y1), entrapment efficiency (Y2), transdermal flux (Y3) were selected as dependent responses (Table 1). The responses were statistically evaluated using Analysis of variance (ANOVA) analysis. Further, The optimum formulation was selected by the numerical point prediction\noptimization procedure using the desirability function (Ahad et al., 2013b, 2014a, 2012)."
    }, {
      "heading" : "2.4. Vesicles size",
      "text" : "The vesicle size and polydispersity index of the developed different nano-invasomes formulations were determined by photon correlation spectroscopy using the Zetasizer 1000HS (Malvern Instruments, Worcestershire, UK). Samples were appropriately diluted with PBS previously filtered through 0.45 mm membrane filter prior to the measurements (Ahad et al., 2013b, 2014b).\n2.5. Entrapment efficiency\nThe entrapment efficiency of developed formulations were estimated by ultracentrifugation method (Imam et al., 2015). Samples were centrifuged in a centrifuge machine (REMI cooling centrifuge, Mumbai) at 14,000 rpm for 3 h at 4 C. The supernatant was collected, appropriately diluted and quantified by UV spectrophotometer (Shimadzu, Japan) at 254 nm (Patel et al., 2011). The percentage of drug entrapment efficiency was calculated by the following equation (Alsarra et al., 2005).\nCa Cb Ca 100\nWhere, Ca = concentration of total olmesartan. Cb = concentration of free olmesartan."
    }, {
      "heading" : "2.6. Nano-invasomes morphology",
      "text" : "Nano-invasomes were visualized using transmission electron microscopy (Philips, CM10, Philips Research, Hamburg, Germany), using an accelerating voltage of 100 Kv. A drop of the sample was placed onto to a carbon coated copper grid to leave a thin film. It was stained with 1% phosphotungstic acid. The grid was allowed to air dry thoroughly and samples were viewed under transmission electron microscope (Madheswaran et al., 2014).\n2.7. Ex-vivo skin permeation study\nEx vivo skin permeation studies were carried out through rat skin using Franz diffusion cells with an effective permeation area\nan loaded nano-invasomes formulations with predicted values generated by Design\nof2 cm2, receptor cell volume of 15 ml. The hair on the skin of animals was clipped and subcutaneous tissues were surgically removed, and dermis side was wiped with isopropyl alcohol to remove residual adhering fat. The skin was washed with PBS, wrapped in aluminum foil and stored in a deep freezer at 20 C till further use (used within 2 weeksofpreparation) (Ahadetal.,2011a).Onthedayofexperiment the rat skin were thawed and the skin sample was mounted on the Franz cells in such a way that stratum corneum side faced the donor compartment whereas the dermis side faced the receiver compartment (Ahad et al., 2011b). To stabilize the skin, initially the donor compartment was kept empty although the receiver compartment was filled with receiver vehicle (saline phosphate buffered, pH 7.4) which was constantly stirred at 600 rpm and maintained at the temperature of 32 1 C. The receiver vehicle was replaced every half an hour to stabilize the skin, which was evident by recording the UV absorption of the receiver vehicle. The zero absorption indicated the complete stabilization (Ahad et al., 2011b; Ali et al., 2014; Amin et al., 2008; Shakeel et al., 2007). After the stabilization of the skin, nano-invasomes formulation (5 ml) was placed in the donor compartment under nonocclusive condition (Trauer et al., 2014). Aliquots of 1 ml werewithdrawn from the receptor compartment via the sampling port at different time intervals i.e. 0,1, 2,4, 8,12 and 24 h and analyzed for drug content by UV–vis spectrophotometer at 254 nm."
    }, {
      "heading" : "2.8. Confocal laser scanning microscopy",
      "text" : "Nano-invasomes formulation loaded with Rhodamine B dye was applied homogeneously and non-occusively to the excised rat abdominal skin mounted on Franz diffusion cell for 18 h. The treated skin was washed with distilled water and cut into small sections and placed on the slide with stratum corneum facing upward and observed using Leica confocal laser scanning microscope (Leica TC SPE- IIw, DMI 4000 RGBV Leica Microsystems, Germany). The skin thickness was optically scanned at 10- 20 mm increments through the z-axis of a confocal microscope (Dayan and Touitou, 2000). Optical excitation was carried out with a 488 nm Argon laser beam, and fluorescence emission was detected above 532 nm. The depth of permeation was measured by Leica Application suite Advance Fluorescence software."
    }, {
      "heading" : "2.9. Formulation of nano-invasomes gel",
      "text" : "The developed nano-invasomes were insufficiently viscous and could therefore be quickly removed from the skin. Therefore, the optimized nano-invasomes formulation was converted into nanoinvasomes gel (Azeem et al., 2009; Valenta and Schultz, 2004). Gel formulation was prepared by dispersing carbopol 9341 (1.25% w/ w) in distilled water. The polymer dispersion was kept aside to allow for the complete swelling of the polymer. Other ingredients like polyethylene glycol 400 (15% w/w) and chlorocresol (0.1% w/ w) were added to above hydrated carbopol 9341 dispersion. Hydrated carbopol dispersion was neutralized with triethanolamine to get clear viscous gel. Then in preformed gel-base, nanoinvasomes formulation was added slowly with gentle stirring, followed by addition of remaining quantity of water to get final formulation (Arellano et al., 1999)."
    }, {
      "heading" : "2.10. Characterization of nano-invasomes gel",
      "text" : ""
    }, {
      "heading" : "2.10.1. pH evaluation",
      "text" : "Nano-invasomes gel was diluted in double distilled water and the pH was recorded using a pH meter (Mettler Toledo MP 220, Greifensee, Switzerland) by bringing it in contact with the gel and allowing it to equilibrate for 1 min (Chaudhary et al., 2011)."
    }, {
      "heading" : "2.10.2. Extrudability, homogeneity and spreadability",
      "text" : "A simple method was adopted for determination of extrudability in term of grams required to extrude a 0.5 cm ribbon of gel in 10 s from a collapsible tube. The homogeneity of the gels was tested by the visual inspection.\nThe spreadability of the gel was determined using the following technique: 0.5 g gel was placed within a circle of 2 cm diameter premarked on a glass plate over which a second glass plate was placed. A weight of 500 g was allowed to rest on the upper glass plate for 5 min (Bachhav and Patravale, 2009). The increase in the diameter due to spreading of the gel was noted. The percent spread by area was calculated using following equation\n% Spread by area = (A2/A1) 100 Where, A1 = 2 cm, and A2 = Final area after spreading."
    }, {
      "heading" : "2.10.3. Drug content",
      "text" : "For determination of drug content, about 1 g of the nanoinvasomes gel was weighed and dissolved in methanol; it was diluted appropriately and analyzed by the UV method (Patel et al., 2011). The drug content is expressed in terms of percentage."
    }, {
      "heading" : "2.10.4. Release kinetics",
      "text" : "To study the drug release kinetics of nano-invasomes gel formulation, data obtained from ex vivo permeation studies were fitted in various kinetic models (Arora et al., 2014; Dhawan et al., 2014; Pawar et al., 2013). Zero order as cumulative percent of drug released versus time, first order as log cumulative percentage of drug remaining versus time, and Higuchi’s model as cumulative percent drug released versus square root of time."
    }, {
      "heading" : "2.11. In vivo pharmacokinetic study",
      "text" : "Pharmacokinetic studies were performed on albino Wistar rats. The animals were received after the study was duly approved by the university animal ethics committee and CPCSEA (Committee for the purpose of control and supervision on experiments on animals) government of India. Wistar rats were kept under standard laboratory conditions in 12 h light/dark cycle at 25 C 2 C and provided with pellet diet (Lipton, Kolkata, India) and water ad libitum. The abdominal area of each rat was shaved just before the experiment and the rats were kept under observation for 24 h for any skin damage that may occur during shaving. The rats were divided into two groups, group 1 was administered oral suspension of olmesartan marketed tablet (BENICAR1) and group 2 received nano-invasomes gel. The blood samples were collected at different time intervals (0, 2, 4, 6, 8, 12, 24 and 48 h) in eppendorf tubes containing di-sodium salt of ethylenediaminetetraacetic acid as an anticoagulant and plasma samples were separated by centrifugating the samples at 5000 rpm (REMI centrifuge, Mumbai, India) for 15 min and samples were stored at 70 C until drug analysis was carried out by HPLC method (Shah et al., 2012). Different pharmacokinetic parameters such as Cmax (the maximum plasma concentration) and Tmax (time to reach maximum plasma concentration) were directly obtained from the plasma concentration versus time curve. The area under the curve from 0 to t (AUC0 48), 0 to 1 (AUC0 1), area under the first moment curve from 0 to 48 (AUMC0 48) 0 to 1 (AUMC0-1) were computed by trapezoid rule and elimination half-life (t1/2) was calculated by using the formula t1/2 = log 2/Kel and elimination rate constant (Kel) was calculated from the slope of log plasma concentration versus time plot."
    }, {
      "heading" : "3. Results and discussion",
      "text" : ""
    }, {
      "heading" : "3.1. Box-Behnken design for preparation and optimization of nanoinvasomes",
      "text" : "A 3-factor, 3-level Box-Behnken design was used to explore quadratic response surfaces and constructing second order polynomial models with Design Expert1. The Box-Behnken design was specifically selected since it requires fewer runs than a central composite design. This cubic design is characterized by set of points lying at the midpoint of each edge of a multidimensional cube and center point replicates, whereas the ‘missing corners’ help the experimenter to avoid the combined factor extremes. This property prevents a potential loss of data in those cases. A design matrix comprising of 15 experimental runs generated by the Design expert software.\nThe independent variables selected were the phospholipid (X1), ethanol (X2), and b-citronellene (X3); while vesicles size (Y1),\nFig. 2. 3D-response surface plot showing effect of independent variables such as phosp efficiency and (C) transdermal flux.\nentrapment efficiency (Y2), and transdermal flux (Y3) were the chosen dependent responses. The results of prepared 15 formulations are given in Table 2. Three dimensional plots were prepared for all the three responses and are shown in Fig. 2, for responses Y1, Y2 and Y3, respectively. These plots are known to study the interaction effects of the factors on the responses as well as are useful in studying the effects of two factors on the response at one time. Fig. 3 quantitatively compared the resultant experimental values of the responses with that of the predicted values."
    }, {
      "heading" : "3.1.1. Response 1 (Y1): effect of independent variables on vesicle size",
      "text" : "Vesicle size is an important variable for assessing the formulation. Smaller the vesicle size larger will be the interfacial surface area for drug absorption. In Eq. (1) it was found that Model F-value of 647.26 implies the model was significant. There was only a 0.01% chance that an F-value this large could occur due to noise. Values of “Prob> F” less than 0.0500 indicate model terms were significant. In this case X1, X2, X3, X1X2, X2X3, X12, X22, X32 were\nholipid, ethanol and b-citronellene on (A) invasomes vesicles size (B) entrapment\nsignificant model terms. Values greater than 0.1000 indicate the model terms were not significant. The “Lack of Fit F-value” of 0.29 implied the lack of Fit was not significant relative to the pure error. There was a 83.30% chance that a “Lack of Fit F-value” this large could occur due to noise. The “predicted R-Squared” of 0.9945 was in reasonable agreement with the “adjusted R-\nSquared” of 0.9976 (Table 3). The ratio of 77.329 indicated an adequate signal. This model can be used to navigate the design space. Adequate precision measures the signal to noise ratio. A ratio greater than 4 was desirable.\nThe polynomial Eq. (1) shows that b–citronellene and phospholipid has a positive effect on vesicles size.\nY1 (vesicles size) = Y1 = +81.14 + 5.29 X1 + 2.33 X2 + 3.34 X3 16.12 X1 X2 9.39 X1 X3 + 1.00 X2 X3 + 32.67 X12 +6.07 X22 9.04 X32 (1)\nConsidering all experiments in Table 2, an average vesicle size was 96.978 nm, with minimum and maximum of 73.65 nm and 138.34 nm, respectively. The concentration of phospholipid has the significant effect on the vesicles size of the nanoinvasomes formulation. It was found that the vesicles size of olmesartan loaded invasomes increased with the increase of phospholipid concentration. Our results are in agreement with previous finding (Dubey et al., 2007; Touitou et al., 2000; Zhaowu et al., 2009).\nThe 3D-graph (Fig. 2A) show that, with the increase in phospholipid concentration from 6% to 12%, the vesicle size of the formulation was also increased in each case (i.e., directly proportional) (Table 2). Formulations F4 and F13, which contained the highest percentage of phospholipid, comparatively showed the larger vesicle size than that of formulations F8 and F3 respectively bearing low percentage of phospholipid.\nA prominent effect of b-citronellene was seen on the vesicle size. It was observed that size of nano-invasomes vesicles was increased when the b-citronellene fraction was increased as seen in Fig. 2(A) and Table 2. The formulation F2 having 1.2% of b-citronellene showed a larger vesicle size as compared to F3, having 0.8% of b-citronellene. It is clear from the data (Table 2) that, there was a gradual increase in the vesicle size from 75.88 nm (formulation F6) to 84.67 nm (F7) when the fraction of b-citronellene in the formulation was increased (Table 2). Similarly vesicle size increased from 73.65 nm (formulation F14) to 78.45 nm (formulation F11) when phospholipid and ethanol concentrations were kept constant.\n3.1.2. Response 2 (Y2): effect of independent variables on entrapment efficiency\nAn UV spectroscopy analysis method was used for the determination of olmesartan entrapment efficiency in nanoinvasomes. The calibration curves of olmesartan were prepared in ethanol: phosphate buffer (3:7 v/v) and found linear over the concentration range of 2–22 mg/ml with regression coefficient (r2) of 0.999. The LOD and LOQ were found to be 1.75 mg/ml and 5.30 mg/ml, respectively. Analytical method was found satisfactory and proved to be adequate for the determination of olmesartan in nano-invasomes formulations.\nIn Eq. (2) it was found that the Model F-value of 275.22 implies the model was significant. There was only a 0.01% chance that a “Model F-value” this large could occur due to noise. Values of “Prob > F” less than 0.0500 indicates model terms were significant. In this case X1, X2, X3, X1X3, X2X3, X12, X22, X32 were significant model terms. Values greater than 0.1000 indicate the model terms were not significant. The “lack of fit F-value” of 0.81 implied the lack of fit was not significant relative to the pure error. There was a 59.37% chance that a “lack of fit F-value” this large could occur due\nto noise. The “predicted R-squared” of 0.9803 was in reasonable agreement with the “adjusted R-squared” of 0.9944 (Table 3). The ratio of 55.753 indicated an adequate signal. This model can be used to navigate the design space. Adequate precision measures the signal to noise ratio. A ratio greater than 4 was desirable.\nY2 (entrapment efficiency) = + 60.25 + 11.82 X1 8.65 X2 + 4.11 X3 1.25 X1 X2 1.21 X1 X3 + 0.99 X2 X3 + 4.55 X12 + 1.27 X22 + 4.30 X32 (2)\nConsidering all experiments in Table 2, averaged olmesartan entrapment efficiency for the 15 runs was found to be 65.65%, with minimum and maximum value of 47.32% and 87.34%, respectively. The phospholipid concentration produced a significant effect on the entrapment efficiency. The 3D-Response graph (Fig. 2B) showed that on increasing the phospholipid content in formulations; higher entrapment efficiency of olmesartan was observed in nano-invasomes. In addition, nature of the drug also plays a significant role in the entrapment efficiency of drug because the drug is entrapped in lipid phase. Olmesartan is a lipophilic drug, so that the entrapment efficiency noticeably was found to be higher.\nIt was observed that the formulations F4, F13, F12, and F15, which contained the highest percentage of phospholipid (12% w/ w), comparatively showed the higher olmesartan entrapment efficiency than that of formulations F8, F3, F2, and F1 respectively which carried the low percentage of phospholipid (6% w/w) (Table 2). Ethanol and terpene also play a substantial role in the entrapment efficiency of drug (Fig. 2B).\n3D-Graph demonstrated that the response Y2 (entrapment efficiency) has inverse relationship with ethanol. The entrapment efficiency decreased substantially with increasing ethanol concentration. This could happen because ethanol makes the vesicles leakier which leads to reduction in entrapment efficiency of nanoinvasomes (Table 2). Formulation F1 (ethanol 5%) showed less entrapment efficiency (47.32%) that the formulation F8 (ethanol 2%) which showed entrapment efficiency of 61.32%. Other factors like phospholipid and terpene are same in concentration in these two formulations. Similar results have been shown by the formulation F4 and F15.\nOn the other hand, terpene (b-citronellene) showed positive relationship with entrapment efficiency of olmesartan. Formulation F2 (b-citronellene 1.2%) showed higher entrapment efficiency (62.21%) than formulation F3 (b-citronellene 0.8%) which exhibited entrapment efficiency of 52.23%. Similar results have been shown by the formulation F12 (b-citronellene 1.2%) which showed higher entrapment efficiency (83.56%) than formulation F13 (b-citronellene 0.8%) which exhibited entrapment efficiency of 78.43% (Table 2). The high entrapment efficiency obtained with the lipophilic terpene b-citronellene is probably due to the particular molecular structure of this compound that can lead to a higher incorporation of olmesartan. It was reported that terpenes act as permeation enhancer by disrupting hydrogen bonds that link ceramides in the skin since alcoholic OH is more electronegative than NH of amide I (Ahad et al., 2011a,b). The presence of\nb-citronellene in the lipid bilayer could have produced the same effect leading to an increased space for the olmesartan incorporation (Mura et al., 2009)."
    }, {
      "heading" : "3.1.3. Response 3 (Y3): effect of independent variables on flux",
      "text" : "In Eq. (3) it was found that the Model F-value of 237.51 implies the model was significant. There was only a 0.01% chance that a “Model F-value” this large could occur due to noise. Values of “Prob > F” less than 0.0500 indicates model terms were significant. In this case X1, X2, X3, X1X2, X1X3, X2X3, X12, X22, X32 were significant model terms. Values greater than 0.1000 indicate the model terms were not significant. The “lack of fit F-value” of 0.44 implied the lack of fit was not significant relative to the pure error. There was a 75.08% chance that a “lack of fit F-value” this large could occur due to noise. The “predicted R-squared” of 0.9820 was in reasonable agreement with the “adjusted Rsquared” of 0.9935 (Table 3). The ratio of 47.239 indicated an adequate signal. This model can be used to navigate the design space. Adequate precision measures the signal to noise ratio. A ratio greater than 4 was desirable.\nY3(Flux) = +14.46 +1.83 X1 + 11.38 X2 + 4.31 X3-2.80 X1 X2 2.03 X1 X3 + 6.27 X2 X3 + 8.78 X12 + 5.00 X22 + 3.31 X32 (3)\nTransdermal flux of olmesartan loaded in nano-invasomes is another important criterion for optimization of nano-invasomes formulation; it was observed from the above equation that the transdermal flux of olmesartan increased on increasing the phospholipid content in the formulation. The 3D-Response graph (Fig. 2C) showed that on increasing the phospholipid content in formulations; higher transdermal flux of olmesartan was observed.\nIt was observed that the formulations F4, and F13 which contained the highest percentage of phospholipid (12% w/w), comparatively showed the higher olmesartan transdermal flux than that of formulations F8, and F3 respectively incorporating low percent of phospholipid (6% w/w) (Table 2). Moreover, the transdermal flux of olmesartan is also increased on increasing ethanol content. A possible explanation is that, when invasomes applied on skin in non-occlusive manner, a prominent part of invasomes is probably disintegrated in their attempt to penetrate into the upper stratum corneum layers, which results in release of terpenes, ethanol, and unsaturated phospholipids. This would be in\nFig. 4. Vesicles size distribution of olme\nagreement with conclusions of many research worker (Hofland et al., 1994; Kirjavainen et al., 1996, 1999b; Zellmer et al., 1995). Thus, the released ethanol, terpenes, and unsaturated phospholipids would be free to exert their penetration-enhancing effect.\nIn addition, penetration of some small intact invasomes into the stratum corneum was also reported, it was suggested that the penetration of small invasomes through stratum corneum bilayers, disturbed due to the effect of ethanol and terpenes on the stratum corneum and the pilosebaceous units appeared to be a major route of invasomes’ penetration into the skin (Dragicevic and Maibach, 2016). Further, high fluidity of invasomes due to the effect of terpenes and ethanol could be the other phenomena which might facilitate the penetration of some small intact invasomes into the stratum corneum (Dragicevic-Curic et al., 2011).\nAntecedently, the penetration of intact vesicles was refused by many researchers (Kirjavainen et al., 1999a, 1996; Zellmer et al., 1995). Later, the penetration of intact deformable vesicles through the skin was proposed by Cevc (2003) and Cevc et al. (2002) . Touitou et al. (2000) showed that ethosomes could penetrate into the stratum corneum bilayers, being disturbed due to the effect of ethanol. Honeywell-Nguyen et al. proposed also the penetration of intact elastic vesicles through channel like regions into the deeper layers of the stratum corneum (Honeywell-Nguyen et al., 2002).\n3D-response graph (Fig. 2C) demonstrated that the transdermal flux (response Y3) has directly proportional relationship with ethanol. Formulation F1 (ethanol 5%) presented higher transdermal flux of 40.43 mg/cm2/h that the formulation F8 (ethanol 2%) which showed transdermal flux of 12.45 mg/cm2/h (Table 2). Similar results have been observed in case of formulation F6 (ethanol 5%) which presented transdermal flux of 23.34 mg/cm2/h while formulation F14 (ethanol 2%) yielded flux of 12.76 mg/cm2/h. Likewise, formulation F15 (ethanol 5%) showed 1.77 times higher enhancement ratio of olmesartan flux over formulation F4 (ethanol 2%).\nTerpene also plays a substantial role in the permeation enhancement of hydrophilic as well as lipophilic drug (Ahad et al., 2009, 2011a,b; Aqil et al., 2007). In our study, terpene such as b-citronellene showed a positive relationship with oflmesartan flux. Formulation F2 (b-citronellene 1.2%) showed higher flux (30.62 mg/cm2/h) than formulation F3 (b-citronellene 0.8%) which presented flux of 18.78 mg/cm2/h. Similarly, formulation F7 (b-citronellene 1.2%) showed 1.94 times enhancement ratio of olmesartan flux over formulation F6 (b-citronellene 0.8%). On\nsartan nano-invasomes formulation.\nsimilar lines, formulation F12 showed better transdermal flux of olmesartan over formulation F13 (Table 2).\nThe optimum formulation of olmesartan nano-invasomes system was selected based on the criteria of attaining the reasonable value of vesicles size, entrapment efficiency and transdermal flux the by applying numerical point prediction optimization method of the Design Expert software1. The formulation composition with phospholipid (11.11 mg), ethanol (4.35%), and b-citronellene (1.09%) was found to fulfill requisites of an optimized olmesartan nano-invasomes formulation.\nVesicles size distribution of optimized olmesartan nanoinvasomes formulation is presented in Fig. 4. In order to investigate the morphology of the optimized formulation, transmission electron microscopy was used. The image (Fig. 5) showed that the drug entrapped in the lipid matrix. They show well-identified spherical vesicles with uniform size distribution, displaying sealed nano-vesicular structure.\nThe optimized olmesartan nano-invasomes formulation presented the experimentally observed values of vesicles size of 83.35 3.25 nm with polydispersity index (0.231 0.012), entrapment efficiency of 65.21 2.25% and transdermal flux of\nFig. 6. Confocal laser microscopy image of rat skin treated with Rhodamin\n32.78 0.703 (mg/cm2/h). These experimental values of vesicles size, entrapment efficiency and transdermal flux yielded by the optimized olmesartan nano-invasomes formulation were found in agreement with the predicted value of vesicles size (94.69 nm), entrapment efficiency (68.47%) and transdermal flux (30.69 mg/ cm2/h) respectively generated by design expert software, suggesting that the optimized formulation was rational and reliable."
    }, {
      "heading" : "3.2. Confocal laser scanning microscopy",
      "text" : "The developed nano-invasomes were well distributed in the skin with high fluorescence intensity as shown by confocal laser scanning microscopy study. The use of the nano-invasomes system resulted in an increase in both depth of penetration (up to about 168 mm) and fluorescence intensity (Fig. 6). This prominently efficient delivery of Rhodamine B probe by nano-invasomes suggests their enhanced penetration and consequent fusion with the membrane lipids in the depths of the skin supporting the hypothesis of many researchers (Chourasia et al., 2011; Dayan and Touitou, 2000; Meng et al., 2013; Shi et al., 2012; Yusuf et al., 2014). It is concluded that nano-invasomes were able to enhance the penetration of a relatively large quantity of the probe deeply into the skin. These results indicate that nano-invasomes may play an important role in promoting drug absorption and applications."
    }, {
      "heading" : "3.3. Evaluation of nano-invasomes gel",
      "text" : "The prepared nano-invasomal gel formulation was smooth with homogeneous appearance and texture. The pH value of prepared nano-invasomes gel was found as 7.0 0.1, which is considered acceptable with no risk of irritation on application to the skin. (Ganeshpurkar et al., 2014). Developed gel of optimized olmesartan nano-invasomes was found to be clear, free from presence of particles and showed good homogeneity with absence of lumps. The spreadability plays a significant role in patient compliance and helps in uniform application of gel to the skin. A good gel takes less time to spread and will have high spreadability. The developed gel of optimized nano-invasomes presented 90% spreadability with\ne B loaded nano-invasomes showing penetration dept of formulation.\nexcellent extrudability i.e. gel is easily spreadable. The drug content of the gel formulation was found to be 99.15 2.71%, showing good content uniformity.\nIn drug release kinetics, the model revealing highest value of R2 (correlation coefficient) was inferred as best model for drug release kinetic. The drug release from nano-invasomes gel through rat skin was fitted into different mathematical models such as zero order release kinetics, first order release kinetics, Higuchi’s square root of time equation (Higuchi, 1963) and Korsmeyer Peppas‘ power law equation (Korsmeyer et al., 1983; Peppas, 1985).\nThe highest value of the correlation coefficient (R2 = 0.986) was observed for Higuchi matrix model, followed by the Korsmeyer– Peppas (R2 = 0.974), first-order (R2 = 0.857) and zero order (R2 = 0.857) models. The correlation coefficients obtained after fitting the in vitro permeation data to the respective model equation indicate that the best fit model was the Higuchi’s model (R2 = 0.986) for nano-invasomes gel. Higuchi describes drug release as a diffusion process based on the Fick’s law, square root time dependent. This relation can be used to describe the drug dissolution from several types of modified release pharmaceutical dosage forms, as in the case of some transdermal systems (Costa and Sousa Lobo, 2001). The same release kinetics for ethosomes formulations was reported by previous researchers (Ghanbarzadeh and Arami, 2013; Mishra et al., 2013; Rakesh and Anoop, 2012).\n3.4. In vivo pharmacokinetic study\nThe analytical method was validated in our laboratory. The peak area ratio of olmesartan to losartan (internal standard) in rat plasma was linear with respect to the analyte concentration over the range 10–1000 ng/ml. For samples preparation protein precipitation method was used. Plasma was taken in an eppendorf tube and spiked with 50 ml of 100 ng/ml solution of losartan. A volume of 200 ml of chilled acetonitrile was added as a protein precipitating agent, vortexed for 1 min and then centrifuged at 10,000 rpm for 10 min. The supernatant layer was separated and reconstituted with 500 ml of mobile phase and vortexed and filtered through 0.45 mm syringe filters and 20 ml of the sample solution was injected for HPLC analysis. Validated analytical method was found satisfactory and proved to be adequate for the determination of olmesartan in plasma.\nThe plasma concentration profile of olmesartan following the application of optimized olmesartan nano-invasomes gel system in Wistar rats is shown in Fig. 7. The Cmax, after application of nanoinvasomes gel was found to be 121.06 9.02 ng/ml, and Tmaxwas\n8 0.41 h. While the Cmax, after oral administration was 177.36 10.55 ng/ml, and Tmax was 2.00 0.22 h (Aqil et al., 2016). This higher value of Tmax after transdermal application was because of barrier property of stratum corneum.\nIt was also observed that AUC0 48, and AUC0-1 of nanoinvasomes gel formulation was 3839.07 202.27 ng h/ml and 5499.87 245.22 ng h/ml. While for oral administration AUC0-48, and AUC0 1 was found to be 3320.99 202.27 ng h/ml and 3842.52 412.33 ng h/ml (Aqil et al., 2016). Although, the Cmax of the transdermal application of nano-invasomes gel was significantly (p < 0.05) lower than the oral tablets, yet the AUC values were significantly higher. This could be due to the maintenance of the concentration of the drug within the pharmacologically effective range for a longer period of time. The significantly (p < 0.05) high AUC0–48 value observed with transdermal nanoinvasomes gel application also indicates increased bioavailability of the drug from transdermal route as compared to oral administration, which could be due to the avoidance of hepatic metabolism by transdermal administration providing high systemic drug availability. The t1/2 of 38.56 1.24 h of olmesartan in plasma was noticed after the application of nano-invasomes gel system, which is approximately, 135% higher as compared to the oral administration. This may be caused by the longer duration of absorption via the transdermal system. The relative bioavailability AUC transdermal/AUC oral was calculated to be 115.60%. In summary, the developed nano-invasomes system has shown better bioavailability of drug and hence, the transdermal route can offer a better alternative to the oral administration with improved bioavailability and lesser dose frequency for the selected drug, olmesartan."
    }, {
      "heading" : "4. Conclusion",
      "text" : "Nano-invasomes of olmesartan were successfully developed and optimized using Box-Behnken design technique in our laboratory. Characterization of formulations revealed that our in-house formulation provided reasonable vesicle size in nanorange, good entrapment efficiency of olmesartan in vesicles and high transdermal flux. In vivo pharmacokinetic study showed that the optimized nano-invasomes gel formulation exhibited 1.15 times improvement in bioavailability of olmesartan in Wistar rats vis-a-vis marketed tablet formulation of olmesartan.\nConflict of interest\nAll authors have approved the final manuscript, and the authors declare that they have no conflicts of interest to disclose."
    } ],
    "references" : [ {
      "title" : "Chemical penetration enhancers: a patent review",
      "author" : [ "A. Ahad", "M. Aqil", "K. Kohli", "H. Chaudhary", "Y. Sultana", "M. Mujeeb", "S. Talegaonkar" ],
      "venue" : "Expert Opin. Ther. Pat",
      "citeRegEx" : "Ahad et al\\.,? \\Q2009\\E",
      "shortCiteRegEx" : "Ahad et al\\.",
      "year" : 2009
    }, {
      "title" : "Interactions between novel terpenes and main components of rat and human skin: mechanistic view for transdermal delivery of propranolol hydrochloride",
      "author" : [ "A. Ahad", "M. Aqil", "K. Kohli", "Y. Sultana", "M. Mujeeb", "A. Ali" ],
      "venue" : "Curr. Drug Deliv",
      "citeRegEx" : "Ahad et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Ahad et al\\.",
      "year" : 2011
    }, {
      "title" : "Role of novel terpenes in transcutaneous permeation of valsartan: effectiveness and mechanism of action",
      "author" : [ "A. Ahad", "M. Aqil", "K. Kohli", "Y. Sultana", "M. Mujeeb", "A. Ali" ],
      "venue" : "Drug Dev. Ind. Pharm",
      "citeRegEx" : "Ahad et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Ahad et al\\.",
      "year" : 2011
    }, {
      "title" : "Formulation and optimization of nanotransfersomes using experimental design technique for accentuated transdermal delivery of valsartan",
      "author" : [ "A. Ahad", "M. Aqil", "K. Kohli", "Y. Sultana", "M. Mujeeb", "A. Ali" ],
      "venue" : "Nanomedicine",
      "citeRegEx" : "Ahad et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Ahad et al\\.",
      "year" : 2012
    }, {
      "title" : "Transdermal delivery of calcium channel blockers for hypertension",
      "author" : [ "A. Ahad", "F.I. Al-Jenoobi", "A.M. Al-Mohizea", "M. Aqil", "K. Kohli" ],
      "venue" : "Expert Opin. Drug Deliv",
      "citeRegEx" : "Ahad et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Ahad et al\\.",
      "year" : 2013
    }, {
      "title" : "Enhanced transdermal delivery of an anti-hypertensive agent via nanoethosomes: statistical optimization, characterization and pharmacokinetic assessment",
      "author" : [ "A. Ahad", "M. Aqil", "K. Kohli", "Y. Sultana", "M. Mujeeb" ],
      "venue" : "Int. J. Pharm",
      "citeRegEx" : "Ahad et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Ahad et al\\.",
      "year" : 2013
    }, {
      "title" : "albino rats",
      "author" : [ "M. Raish", "A.M. Al-Mohizea", "F.I. Al-Jenoobi", "M.A. Alam" ],
      "venue" : "Expert Opin. Drug Deliv",
      "citeRegEx" : "A. et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "A. et al\\.",
      "year" : 2014
    }, {
      "title" : "Transdermal delivery",
      "author" : [ "Saudi Pharm. J", "A. 587–602. Ahad", "A.M. Al-Mohizea", "F.I. Al-Jenoobi", "M. Aqil" ],
      "venue" : null,
      "citeRegEx" : "23 et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "23 et al\\.",
      "year" : 2016
    }, {
      "title" : "Preparation, characterization and",
      "author" : [ "M.S. 579–590. Ali", "M.S. Alam", "N. Alam", "M.R. Siddiqui" ],
      "venue" : null,
      "citeRegEx" : "Ali et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Ali et al\\.",
      "year" : 2014
    }, {
      "title" : "Mechanism of in vitro",
      "author" : [ "S. Amin", "K. Kohli", "R.K. Khar", "S.R. Mir", "K.K. Pillai" ],
      "venue" : null,
      "citeRegEx" : "490",
      "shortCiteRegEx" : "490",
      "year" : 2008
    }, {
      "title" : "Hypertension in India: a systematic review and meta",
      "author" : [ "D. Prabhakaran" ],
      "venue" : null,
      "citeRegEx" : "Prabhakaran,? \\Q2014\\E",
      "shortCiteRegEx" : "Prabhakaran",
      "year" : 2014
    }, {
      "title" : "Status of terpenes as skin penetration",
      "author" : [ "M. 1170–1177. Aqil", "A. Ahad", "Y. Sultana", "A. Ali" ],
      "venue" : null,
      "citeRegEx" : "Aqil et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Aqil et al\\.",
      "year" : 2007
    }, {
      "title" : "optimization and pharmacokinetic evaluation",
      "author" : [ "A. Arellano", "S. Santoyo", "C. Martin", "P. Ygartua" ],
      "venue" : "J. Mol. Liq",
      "citeRegEx" : "Arellano et al\\.,? \\Q1999\\E",
      "shortCiteRegEx" : "Arellano et al\\.",
      "year" : 1999
    }, {
      "title" : "Nanoemulsion based hydrogel",
      "author" : [ "G. Aggarwal", "S.L. Harikumar", "K. Kaur" ],
      "venue" : "sodium from carbopol gels. Eur. J. Pharm. Sci",
      "citeRegEx" : "R. et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "R. et al\\.",
      "year" : 2014
    }, {
      "title" : "Microemulsion based vaginal gel of fluconazole",
      "author" : [ "Y.G. 1093–1103. Bachhav", "V.B. Patravale" ],
      "venue" : null,
      "citeRegEx" : "Bachhav and Patravale,? \\Q2009\\E",
      "shortCiteRegEx" : "Bachhav and Patravale",
      "year" : 2009
    }, {
      "title" : "Ultradeformable lipid vesicles",
      "author" : [ "G. S13–16. Cevc", "A. Schatzlein", "H. Richardsen" ],
      "venue" : "a concise overview. J. Hum. Hypertens",
      "citeRegEx" : "Cevc et al\\.,? \\Q2002\\E",
      "shortCiteRegEx" : "Cevc et al\\.",
      "year" : 2002
    }, {
      "title" : "Modeling and comparison of dissolution profiles",
      "author" : [ "J.M. Sousa Lobo" ],
      "venue" : "transdermal delivery. Results Pharm. Sci",
      "citeRegEx" : "P. and Lobo,? \\Q2001\\E",
      "shortCiteRegEx" : "P. and Lobo",
      "year" : 2001
    }, {
      "title" : "Carriers for skin delivery of trihexyphenidyl HCl",
      "author" : [ "E. Touitou" ],
      "venue" : "Eur. J. Pharm. Sci",
      "citeRegEx" : "N. and Touitou,? \\Q2000\\E",
      "shortCiteRegEx" : "N. and Touitou",
      "year" : 2000
    }, {
      "title" : "ethosomes vs. liposomes",
      "author" : [ "B. Dhawan", "G. Aggarwal", "S. Harikumar" ],
      "venue" : null,
      "citeRegEx" : "Dhawan et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Dhawan et al\\.",
      "year" : 2014
    }, {
      "title" : "Topical application",
      "author" : [ "S. Grafe", "V. Albrecht", "A. Fahr" ],
      "venue" : null,
      "citeRegEx" : "10",
      "shortCiteRegEx" : "10",
      "year" : 2008
    }, {
      "title" : "implanted tumours in mice: a pilot study",
      "author" : [ "N. Dragicevic-Curic", "D. Scheglmann", "V. Albrecht", "A. Fahr" ],
      "venue" : "J. Photochem. Photobiol. B",
      "citeRegEx" : "Dragicevic.Curic et al\\.,? \\Q2008\\E",
      "shortCiteRegEx" : "Dragicevic.Curic et al\\.",
      "year" : 2008
    }, {
      "title" : "Assessment of fluidity of different invasomes by electron",
      "author" : [ "W. Plass", "A. Fahr" ],
      "venue" : null,
      "citeRegEx" : "Plass and Fahr,? \\Q2011\\E",
      "shortCiteRegEx" : "Plass and Fahr",
      "year" : 2011
    }, {
      "title" : "Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes",
      "author" : [ "V. Dubey", "D. Mishra", "T. Dutta", "M. Nahar", "D.K. Saraf", "N.K. Jain" ],
      "venue" : "J. Control. Release",
      "citeRegEx" : "Dubey et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Dubey et al\\.",
      "year" : 2007
    }, {
      "title" : "Delivery of amphotericin B for effective treatment of candida albicans induced dermal mycosis in rats via emulgel system: formulation and evaluation",
      "author" : [ "A. Ganeshpurkar", "P. Vaishya", "S. Jain", "V. Pandey", "D. Bansal", "N. Dubey" ],
      "venue" : "Indian J. Dermatol",
      "citeRegEx" : "Ganeshpurkar et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Ganeshpurkar et al\\.",
      "year" : 2014
    }, {
      "title" : "Enhanced transdermal delivery of diclofenac sodium via conventional liposomes, ethosomes, and transfersomes",
      "author" : [ "S. Ghanbarzadeh", "S. Arami" ],
      "venue" : "Biomed. Res",
      "citeRegEx" : "Ghanbarzadeh and Arami,? \\Q2013\\E",
      "shortCiteRegEx" : "Ghanbarzadeh and Arami",
      "year" : 2013
    }, {
      "title" : "Systemic delivery of antihypertensive drugs via skin",
      "author" : [ "S. Gungor", "Y. Ozsoy" ],
      "venue" : "Ther. Deliv",
      "citeRegEx" : "Gungor and Ozsoy,? \\Q2012\\E",
      "shortCiteRegEx" : "Gungor and Ozsoy",
      "year" : 2012
    }, {
      "title" : "Development and characterization of colloidal soft nano-carriers for transdermal delivery and bioavailability enhancement of an angiotensin II receptor blocker",
      "author" : [ "R.M. Hathout", "A.H. Elshafeey" ],
      "venue" : "Eur. J. Pharm. Biopharm",
      "citeRegEx" : "Hathout and Elshafeey,? \\Q2012\\E",
      "shortCiteRegEx" : "Hathout and Elshafeey",
      "year" : 2012
    }, {
      "title" : "Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices",
      "author" : [ "T. Higuchi" ],
      "venue" : "J. Pharm. Sci",
      "citeRegEx" : "Higuchi,? \\Q1963\\E",
      "shortCiteRegEx" : "Higuchi",
      "year" : 1963
    }, {
      "title" : "Estradiol permeation from nonionic surfactant vesicles through human stratum corneum in vitro",
      "author" : [ "H.E. Hofland", "R. van der Geest", "H.E. Bodde", "H.E. Junginger", "J.A. Bouwstra" ],
      "venue" : "Pharm. Res",
      "citeRegEx" : "Hofland et al\\.,? \\Q1994\\E",
      "shortCiteRegEx" : "Hofland et al\\.",
      "year" : 1994
    }, {
      "title" : "The in vivo and in vitro interactions of elastic and rigid vesicles with human skin",
      "author" : [ "P.L. Honeywell-Nguyen", "A.M. de Graaff", "H.W. Groenink", "J.A. Bouwstra" ],
      "venue" : "Biochim. Biophys. Acta",
      "citeRegEx" : "Honeywell.Nguyen et al\\.,? \\Q2002\\E",
      "shortCiteRegEx" : "Honeywell.Nguyen et al\\.",
      "year" : 2002
    }, {
      "title" : "Formulation by designbased proniosome for accentuated transdermal delivery of risperidone: in vitro characterization and in vivo pharmacokinetic study",
      "author" : [ "S.S. Imam", "M. Aqil", "M. Akhtar", "Y. Sultana", "A. Ali" ],
      "venue" : "Drug Deliv",
      "citeRegEx" : "Imam et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Imam et al\\.",
      "year" : 2015
    }, {
      "title" : "Global burden of hypertension: analysis of worldwide data",
      "author" : [ "P.M. Kearney", "M. Whelton", "K. Reynolds", "P. Muntner", "P.K. Whelton", "J. He" ],
      "venue" : null,
      "citeRegEx" : "Kearney et al\\.,? \\Q2005\\E",
      "shortCiteRegEx" : "Kearney et al\\.",
      "year" : 2005
    }, {
      "title" : "Interaction of liposomes with human skin in vitro–the influence of lipid composition and structure",
      "author" : [ "M. Kirjavainen", "A. Urtti", "I. Jaaskelainen", "T.M. Suhonen", "P. Paronen", "R. ValjakkaKoskela", "J. Kiesvaara", "J. Monkkonen" ],
      "venue" : "Biochim. Biophys",
      "citeRegEx" : "Kirjavainen et al\\.,? \\Q1996\\E",
      "shortCiteRegEx" : "Kirjavainen et al\\.",
      "year" : 1996
    }, {
      "title" : "Phospholipids affect stratum corneum lipid bilayer fluidity and drug partitioning into the bilayers",
      "author" : [ "M. Kirjavainen", "J. Monkkonen", "M. Saukkosaari", "R. Valjakka-Koskela", "J. Kiesvaara", "A. Urtti" ],
      "venue" : "J. Control. Release",
      "citeRegEx" : "Kirjavainen et al\\.,? \\Q1999\\E",
      "shortCiteRegEx" : "Kirjavainen et al\\.",
      "year" : 1999
    }, {
      "title" : "Liposome-skin interactions and their effects on the skin permeation of drugs",
      "author" : [ "M. Kirjavainen", "A. Urtti", "R. Valjakka-Koskela", "J. Kiesvaara", "J. Monkkonen" ],
      "venue" : "Eur. J. Pharm. Sci",
      "citeRegEx" : "Kirjavainen et al\\.,? \\Q1999\\E",
      "shortCiteRegEx" : "Kirjavainen et al\\.",
      "year" : 1999
    }, {
      "title" : "Mechanism of solute release from porous hydrophilic polymers",
      "author" : [ "R.W. Korsmeyer", "R. Gurny", "E.M. Doelker", "P. Buri", "N.A. Peppas" ],
      "venue" : "Int. J. Pharm",
      "citeRegEx" : "Korsmeyer et al\\.,? \\Q1983\\E",
      "shortCiteRegEx" : "Korsmeyer et al\\.",
      "year" : 1983
    }, {
      "title" : "The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction",
      "author" : [ "P. Laeis", "K. Puchler", "W. Kirch" ],
      "venue" : "J. Hypertens",
      "citeRegEx" : "Laeis et al\\.,? \\Q2001\\E",
      "shortCiteRegEx" : "Laeis et al\\.",
      "year" : 2001
    }, {
      "title" : "Enhanced topical delivery of finasteride using glyceryl monooleate-based liquid crystalline nanoparticles stabilized by cremophor surfactants",
      "author" : [ "T. Madheswaran", "R. Baskaran", "C.S. Yong", "B.K. Yoo" ],
      "venue" : "AAPS PharmSciTech",
      "citeRegEx" : "Madheswaran et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Madheswaran et al\\.",
      "year" : 2014
    }, {
      "title" : "Enhanced transdermal bioavailability of testosterone propionate via surfactant-modified ethosomes",
      "author" : [ "S. Meng", "Z. Chen", "L. Yang", "W. Zhang", "D. Liu", "J. Guo", "Y. Guan", "J. Li" ],
      "venue" : "Int. J. Nanomed",
      "citeRegEx" : "Meng et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Meng et al\\.",
      "year" : 2013
    }, {
      "title" : "Formulation and optimization of ethosomes for transdermal delivery of ropinirole hydrochloride",
      "author" : [ "A.D. Mishra", "C.N. Patel", "D.R. Shah" ],
      "venue" : "Curr. Drug Deliv",
      "citeRegEx" : "Mishra et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Mishra et al\\.",
      "year" : 2013
    }, {
      "title" : "Penetration enhancer-containing vesicles (PEVs) as carriers for cutaneous delivery of minoxidil",
      "author" : [ "S. Mura", "M. Manconi", "C. Sinico", "D. Valenti", "A.M. Fadda" ],
      "venue" : "Int. J. Pharm",
      "citeRegEx" : "Mura et al\\.,? \\Q2009\\E",
      "shortCiteRegEx" : "Mura et al\\.",
      "year" : 2009
    }, {
      "title" : "Gender difference in blood pressure control and cardiovascular risk factors in Americans with diagnosed hypertension",
      "author" : [ "K.L. Ong", "A.W. Tso", "K.S. Lam", "B.M. Cheung" ],
      "venue" : "Hypertension",
      "citeRegEx" : "Ong et al\\.,? \\Q2008\\E",
      "shortCiteRegEx" : "Ong et al\\.",
      "year" : 2008
    }, {
      "title" : "Development of the UV spectrophotometric method of Olmesartan medoxomil in bulk drug and pharmaceutical formulation and stress degradation studies",
      "author" : [ "J. Patel", "G. Kevin", "A. Patel", "M. Raval", "N. Sheth" ],
      "venue" : "Pharm. Methods",
      "citeRegEx" : "Patel et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Patel et al\\.",
      "year" : 2011
    }, {
      "title" : "Hp-beta-CD-voriconazole in situ gelling system for ocular drug delivery: in vitro, stability, and antifungal activities assessment",
      "author" : [ "P. Pawar", "H. Kashyap", "S. Malhotra", "R. Sindhu" ],
      "venue" : "Biomed. Res",
      "citeRegEx" : "Pawar et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Pawar et al\\.",
      "year" : 2013
    }, {
      "title" : "Analysis of Fickian and non-Fickian drug release from polymers",
      "author" : [ "N.A. Peppas" ],
      "venue" : "Pharm. Acta Helv",
      "citeRegEx" : "Peppas,? \\Q1985\\E",
      "shortCiteRegEx" : "Peppas",
      "year" : 1985
    }, {
      "title" : "Invasomes of isradipine for enhanced transdermal delivery against hypertension: formulation, characterization, and in vivo pharmacodynamic study",
      "author" : [ "G.R. Qadri", "A. Ahad", "M. Aqil", "S.S. Imam", "A. Ali" ],
      "venue" : "Artif. Cells Nanomed. Biotechnol",
      "citeRegEx" : "Qadri et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Qadri et al\\.",
      "year" : 2016
    }, {
      "title" : "Formulation and optimization of nano-sized ethosomes for enhanced transdermal delivery of cromolyn sodium",
      "author" : [ "R. Rakesh", "K.R. Anoop" ],
      "venue" : "J. Pharm. Bioall. Sci",
      "citeRegEx" : "Rakesh and Anoop,? \\Q2012\\E",
      "shortCiteRegEx" : "Rakesh and Anoop",
      "year" : 2012
    }, {
      "title" : "Olmesartan medoxomil: a review of its use in the management of hypertension",
      "author" : [ "L.J. Scott", "P.L. McCormack" ],
      "venue" : "Drugs",
      "citeRegEx" : "Scott and McCormack,? \\Q2008\\E",
      "shortCiteRegEx" : "Scott and McCormack",
      "year" : 2008
    }, {
      "title" : "Transdermal drug delivery systems for antihypertensive drugs—a review",
      "author" : [ "R.P. Selvam", "A.K. Singh", "T. Sivakumar" ],
      "venue" : "Int. J. Pharm. Biomed. Res",
      "citeRegEx" : "Selvam et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Selvam et al\\.",
      "year" : 2010
    }, {
      "title" : "Simultaneous quantitative analysis of olmesartan medoxomil and amlodipine besylate in plasma by high-performance liquid chromatography technique",
      "author" : [ "S. Shah", "A. Asnani", "D. Kawade", "S. Dangre", "S. Arora", "S. Yende" ],
      "venue" : "J. Young Pharm",
      "citeRegEx" : "Shah et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Shah et al\\.",
      "year" : 2012
    }, {
      "title" : "LeciPlex, invasomes, and liposomes: a skin penetration study",
      "author" : [ "S.M. Shah", "M. Ashtikar", "A.S. Jain", "D.T. Makhija", "Y. Nikam", "R.P. Gude", "F. Steiniger", "A.A. Jagtap", "M.S. Nagarsenker", "A. Fahr" ],
      "venue" : "Int. J. Pharm",
      "citeRegEx" : "Shah et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Shah et al\\.",
      "year" : 2015
    }, {
      "title" : "Nanoemulsions as vehicles for transdermal delivery of aceclofenac",
      "author" : [ "F. Shakeel", "S. Baboota", "A. Ahuja", "J. Ali", "M. Aqil", "S. Shafiq" ],
      "venue" : "AAPS PharmSciTech",
      "citeRegEx" : "Shakeel et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Shakeel et al\\.",
      "year" : 2007
    }, {
      "title" : "Ligustrazine phosphate ethosomes for treatment of Alzheimer's disease, in vitro and in animal model studies",
      "author" : [ "J. Shi", "Y. Wang", "G. Luo" ],
      "venue" : "AAPS PharmSciTech",
      "citeRegEx" : "Shi et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Shi et al\\.",
      "year" : 2012
    }, {
      "title" : "Ethosomes novel vesicular carriers for enhanced delivery: characterization and skin penetration properties",
      "author" : [ "E. Touitou", "N. Dayan", "L. Bergelson", "B. Godin", "M. Eliaz" ],
      "venue" : "J. Control. Release",
      "citeRegEx" : "Touitou et al\\.,? \\Q2000\\E",
      "shortCiteRegEx" : "Touitou et al\\.",
      "year" : 2000
    }, {
      "title" : "Influence of massage",
      "author" : [ "S. Trauer", "H. Richter", "J. Kuntsche", "R. Buttemeyer", "M. Liebsch", "M. Linscheid", "A. Fahr", "M. Schafer-Korting", "J. Lademann", "A. Patzelt" ],
      "venue" : null,
      "citeRegEx" : "Trauer et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Trauer et al\\.",
      "year" : 2014
    }, {
      "title" : "Influence of carrageenan on the rheology and skin permeation of microemulsion formulations",
      "author" : [ "C. Valenta", "K. Schultz" ],
      "venue" : "J. Control. Release",
      "citeRegEx" : "Valenta and Schultz,? \\Q2004\\E",
      "shortCiteRegEx" : "Valenta and Schultz",
      "year" : 2004
    }, {
      "title" : "Nanovesicles for transdermal delivery of felodipine: development, characterization, and pharmacokinetics",
      "author" : [ "M. Yusuf", "V. Sharma", "K. Pathak" ],
      "venue" : "Int. J. Pharm. Investig",
      "citeRegEx" : "Yusuf et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Yusuf et al\\.",
      "year" : 2014
    }, {
      "title" : "Interaction of phosphatidylcholine liposomes with the human stratum corneum",
      "author" : [ "S. Zellmer", "W. Pfeil", "J. Lasch" ],
      "venue" : "Biochim. Biophys. Acta",
      "citeRegEx" : "Zellmer et al\\.,? \\Q1995\\E",
      "shortCiteRegEx" : "Zellmer et al\\.",
      "year" : 1995
    }, {
      "title" : "Preparation of matrine ethosome, its percutaneous permeation in vitro and anti-inflammatory activity in vivo in rats",
      "author" : [ "Z. Zhaowu", "W. Xiaoli", "Z. Yangde", "L. Nianfeng" ],
      "venue" : "J. Liposome Res",
      "citeRegEx" : "Zhaowu et al\\.,? \\Q2009\\E",
      "shortCiteRegEx" : "Zhaowu et al\\.",
      "year" : 2009
    } ],
    "referenceMentions" : [ {
      "referenceID" : 31,
      "context" : "9% of Indian women were suffering from hypertension in 2005 (Anchala et al., 2014; Kearney et al., 2005).",
      "startOffset" : 60,
      "endOffset" : 104
    }, {
      "referenceID" : 31,
      "context" : "6 for Indian men and women, respectively by 2025 (Kearney et al., 2005).",
      "startOffset" : 49,
      "endOffset" : 71
    }, {
      "referenceID" : 25,
      "context" : "Many attempts have been made globally at the laboratory level to develop transdermal system of various antihypertensive drugs (Ahad et al., 2015a, 2013a, 2016; Gungor and Ozsoy, 2012; Selvam et al., 2010).",
      "startOffset" : 126,
      "endOffset" : 204
    }, {
      "referenceID" : 48,
      "context" : "Many attempts have been made globally at the laboratory level to develop transdermal system of various antihypertensive drugs (Ahad et al., 2015a, 2013a, 2016; Gungor and Ozsoy, 2012; Selvam et al., 2010).",
      "startOffset" : 126,
      "endOffset" : 204
    }, {
      "referenceID" : 47,
      "context" : "Oral olmesartan 10–40 mg once daily is recommended for the treatment of adult patients with hypertension (Scott and McCormack, 2008).",
      "startOffset" : 105,
      "endOffset" : 132
    }, {
      "referenceID" : 26,
      "context" : "Above properties of olmesartan makes it a good candidate for the development of TTS (Ahad et al., 2016; Aqil et al., 2016; Hathout and Elshafeey, 2012).",
      "startOffset" : 84,
      "endOffset" : 151
    }, {
      "referenceID" : 50,
      "context" : "This system has shown to improve skin penetration of hydrophilic and lipophilic drugs (Dragicevic-Curic et al., 2008a,b, 2009a,b; Shah et al., 2015).",
      "startOffset" : 86,
      "endOffset" : 148
    }, {
      "referenceID" : 11,
      "context" : "Ethanol is a good penetration enhancer while terpenes have also shown potential to increase the penetration of many drugs by disrupting the tight lipid packing of the stratum corneum (Aqil et al., 2007).",
      "startOffset" : 183,
      "endOffset" : 202
    }, {
      "referenceID" : 45,
      "context" : "Very recently, invasomes prepared using b-citronellene were described as carriers for skin deposition of isradipine (Qadri et al., 2016).",
      "startOffset" : 116,
      "endOffset" : 136
    }, {
      "referenceID" : 50,
      "context" : "10 ml of nano-invasomes were prepared by the method as reported elsewhere (Shah et al., 2015).",
      "startOffset" : 74,
      "endOffset" : 93
    }, {
      "referenceID" : 30,
      "context" : "The entrapment efficiency of developed formulations were estimated by ultracentrifugation method (Imam et al., 2015).",
      "startOffset" : 97,
      "endOffset" : 116
    }, {
      "referenceID" : 42,
      "context" : "The supernatant was collected, appropriately diluted and quantified by UV spectrophotometer (Shimadzu, Japan) at 254 nm (Patel et al., 2011).",
      "startOffset" : 120,
      "endOffset" : 140
    }, {
      "referenceID" : 37,
      "context" : "The grid was allowed to air dry thoroughly and samples were viewed under transmission electron microscope (Madheswaran et al., 2014).",
      "startOffset" : 106,
      "endOffset" : 132
    }, {
      "referenceID" : 8,
      "context" : "The zero absorption indicated the complete stabilization (Ahad et al., 2011b; Ali et al., 2014; Amin et al., 2008; Shakeel et al., 2007).",
      "startOffset" : 57,
      "endOffset" : 136
    }, {
      "referenceID" : 51,
      "context" : "The zero absorption indicated the complete stabilization (Ahad et al., 2011b; Ali et al., 2014; Amin et al., 2008; Shakeel et al., 2007).",
      "startOffset" : 57,
      "endOffset" : 136
    }, {
      "referenceID" : 54,
      "context" : "After the stabilization of the skin, nano-invasomes formulation (5 ml) was placed in the donor compartment under nonocclusive condition (Trauer et al., 2014).",
      "startOffset" : 136,
      "endOffset" : 157
    }, {
      "referenceID" : 55,
      "context" : "Therefore, the optimized nano-invasomes formulation was converted into nanoinvasomes gel (Azeem et al., 2009; Valenta and Schultz, 2004).",
      "startOffset" : 89,
      "endOffset" : 136
    }, {
      "referenceID" : 14,
      "context" : "A weight of 500 g was allowed to rest on the upper glass plate for 5 min (Bachhav and Patravale, 2009).",
      "startOffset" : 73,
      "endOffset" : 102
    }, {
      "referenceID" : 42,
      "context" : "For determination of drug content, about 1 g of the nanoinvasomes gel was weighed and dissolved in methanol; it was diluted appropriately and analyzed by the UV method (Patel et al., 2011).",
      "startOffset" : 168,
      "endOffset" : 188
    }, {
      "referenceID" : 18,
      "context" : "To study the drug release kinetics of nano-invasomes gel formulation, data obtained from ex vivo permeation studies were fitted in various kinetic models (Arora et al., 2014; Dhawan et al., 2014; Pawar et al., 2013).",
      "startOffset" : 154,
      "endOffset" : 215
    }, {
      "referenceID" : 43,
      "context" : "To study the drug release kinetics of nano-invasomes gel formulation, data obtained from ex vivo permeation studies were fitted in various kinetic models (Arora et al., 2014; Dhawan et al., 2014; Pawar et al., 2013).",
      "startOffset" : 154,
      "endOffset" : 215
    }, {
      "referenceID" : 49,
      "context" : "The blood samples were collected at different time intervals (0, 2, 4, 6, 8, 12, 24 and 48 h) in eppendorf tubes containing di-sodium salt of ethylenediaminetetraacetic acid as an anticoagulant and plasma samples were separated by centrifugating the samples at 5000 rpm (REMI centrifuge, Mumbai, India) for 15 min and samples were stored at 70 C until drug analysis was carried out by HPLC method (Shah et al., 2012).",
      "startOffset" : 397,
      "endOffset" : 416
    }, {
      "referenceID" : 22,
      "context" : "Our results are in agreement with previous finding (Dubey et al., 2007; Touitou et al., 2000; Zhaowu et al., 2009).",
      "startOffset" : 51,
      "endOffset" : 114
    }, {
      "referenceID" : 53,
      "context" : "Our results are in agreement with previous finding (Dubey et al., 2007; Touitou et al., 2000; Zhaowu et al., 2009).",
      "startOffset" : 51,
      "endOffset" : 114
    }, {
      "referenceID" : 58,
      "context" : "Our results are in agreement with previous finding (Dubey et al., 2007; Touitou et al., 2000; Zhaowu et al., 2009).",
      "startOffset" : 51,
      "endOffset" : 114
    }, {
      "referenceID" : 40,
      "context" : "b-citronellene in the lipid bilayer could have produced the same effect leading to an increased space for the olmesartan incorporation (Mura et al., 2009).",
      "startOffset" : 135,
      "endOffset" : 154
    }, {
      "referenceID" : 28,
      "context" : "Vesicles size distribution of olme agreement with conclusions of many research worker (Hofland et al., 1994; Kirjavainen et al., 1996, 1999b; Zellmer et al., 1995).",
      "startOffset" : 86,
      "endOffset" : 163
    }, {
      "referenceID" : 57,
      "context" : "Vesicles size distribution of olme agreement with conclusions of many research worker (Hofland et al., 1994; Kirjavainen et al., 1996, 1999b; Zellmer et al., 1995).",
      "startOffset" : 86,
      "endOffset" : 163
    }, {
      "referenceID" : 57,
      "context" : "Antecedently, the penetration of intact vesicles was refused by many researchers (Kirjavainen et al., 1999a, 1996; Zellmer et al., 1995).",
      "startOffset" : 81,
      "endOffset" : 136
    }, {
      "referenceID" : 29,
      "context" : "proposed also the penetration of intact elastic vesicles through channel like regions into the deeper layers of the stratum corneum (Honeywell-Nguyen et al., 2002).",
      "startOffset" : 132,
      "endOffset" : 163
    }, {
      "referenceID" : 11,
      "context" : "Terpene also plays a substantial role in the permeation enhancement of hydrophilic as well as lipophilic drug (Ahad et al., 2009, 2011a,b; Aqil et al., 2007).",
      "startOffset" : 110,
      "endOffset" : 157
    }, {
      "referenceID" : 38,
      "context" : "This prominently efficient delivery of Rhodamine B probe by nano-invasomes suggests their enhanced penetration and consequent fusion with the membrane lipids in the depths of the skin supporting the hypothesis of many researchers (Chourasia et al., 2011; Dayan and Touitou, 2000; Meng et al., 2013; Shi et al., 2012; Yusuf et al., 2014).",
      "startOffset" : 230,
      "endOffset" : 336
    }, {
      "referenceID" : 52,
      "context" : "This prominently efficient delivery of Rhodamine B probe by nano-invasomes suggests their enhanced penetration and consequent fusion with the membrane lipids in the depths of the skin supporting the hypothesis of many researchers (Chourasia et al., 2011; Dayan and Touitou, 2000; Meng et al., 2013; Shi et al., 2012; Yusuf et al., 2014).",
      "startOffset" : 230,
      "endOffset" : 336
    }, {
      "referenceID" : 56,
      "context" : "This prominently efficient delivery of Rhodamine B probe by nano-invasomes suggests their enhanced penetration and consequent fusion with the membrane lipids in the depths of the skin supporting the hypothesis of many researchers (Chourasia et al., 2011; Dayan and Touitou, 2000; Meng et al., 2013; Shi et al., 2012; Yusuf et al., 2014).",
      "startOffset" : 230,
      "endOffset" : 336
    }, {
      "referenceID" : 27,
      "context" : "The drug release from nano-invasomes gel through rat skin was fitted into different mathematical models such as zero order release kinetics, first order release kinetics, Higuchi’s square root of time equation (Higuchi, 1963) and Korsmeyer Peppas‘ power law equation (Korsmeyer et al.",
      "startOffset" : 210,
      "endOffset" : 225
    }, {
      "referenceID" : 35,
      "context" : "The drug release from nano-invasomes gel through rat skin was fitted into different mathematical models such as zero order release kinetics, first order release kinetics, Higuchi’s square root of time equation (Higuchi, 1963) and Korsmeyer Peppas‘ power law equation (Korsmeyer et al., 1983; Peppas, 1985).",
      "startOffset" : 267,
      "endOffset" : 305
    }, {
      "referenceID" : 44,
      "context" : "The drug release from nano-invasomes gel through rat skin was fitted into different mathematical models such as zero order release kinetics, first order release kinetics, Higuchi’s square root of time equation (Higuchi, 1963) and Korsmeyer Peppas‘ power law equation (Korsmeyer et al., 1983; Peppas, 1985).",
      "startOffset" : 267,
      "endOffset" : 305
    }, {
      "referenceID" : 24,
      "context" : "The same release kinetics for ethosomes formulations was reported by previous researchers (Ghanbarzadeh and Arami, 2013; Mishra et al., 2013; Rakesh and Anoop, 2012).",
      "startOffset" : 90,
      "endOffset" : 165
    }, {
      "referenceID" : 39,
      "context" : "The same release kinetics for ethosomes formulations was reported by previous researchers (Ghanbarzadeh and Arami, 2013; Mishra et al., 2013; Rakesh and Anoop, 2012).",
      "startOffset" : 90,
      "endOffset" : 165
    }, {
      "referenceID" : 46,
      "context" : "The same release kinetics for ethosomes formulations was reported by previous researchers (Ghanbarzadeh and Arami, 2013; Mishra et al., 2013; Rakesh and Anoop, 2012).",
      "startOffset" : 90,
      "endOffset" : 165
    } ],
    "year" : 2016,
    "abstractText" : "Olmesartan is a hydrophobic antihypertensive drug with a short biological half-life, and low bioavailability, presents a challenge with respect to its oral administration. The objective of the work was to formulate, optimize and evaluate the transdermal potential of novel vesicular nano-invasomes, containing above anti-hypertensive agent. To achieve the above purpose, soft carriers (viz. nanoinvasomes) of olmesartan with b-citronellene as potential permeation enhancer were developed and optimized using Box-Behnken design. The physicochemical characteristics e.g., vesicle size, shape, entrapment efficiency and skin permeability of the nano-invasomes formulations were evaluated. The optimized formulation was further evaluated for in vitro drug release, confocal microscopy and in vivo pharmacokinetic study. The optimum nano-invasomes formulation showed vesicles size of 83.35 3.25 nm, entrapment efficiency of 65.21 2.25% and transdermal flux of 32.78 0.703 (mg/ cm/h) which were found in agreement with the predicted value generated by Box-Behnken design. Confocal laser microscopy of rat skin showed that optimized formulation was eventually distributed and permeated deep into the skin. The pharmacokinetic study presented that transdermal nano-invasomes formulation showed 1.15 times improvement in bioavailability of olmesartan with respect to the control formulation in Wistar rats. It was concluded that the response surfaces estimated by Design Expert illustrated obvious relationship between formulation factors and response variables and nano-invasomes were found to be a proficient carrier system for transdermal delivery of olmesartan. ã 2016 Elsevier B.V. All rights reserved.",
    "creator" : "Elsevier"
  }
}